Prevention of stroke for clinical purposes

被引:0
作者
Grotemeyer, K-H. [1 ]
Grotemeyer, K. C. [1 ]
机构
[1] Klinikum Saarbrucken, Neurol Klin, D-66119 Saarbrucken, Germany
关键词
Stroke; secondary prevention; aggregation inhibitors; anti-coagulation; costs; ACETYLSALICYLIC-ACID; SECONDARY PREVENTION; ATRIAL-FIBRILLATION; DOUBLE-BLIND; ASPIRIN; CLOPIDOGREL; TRIAL; RISK; DIPYRIDAMOLE; ATORVASTATIN;
D O I
10.1055/s-0038-1627161
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The physician knows the guidelines from the German Neurology Society (DGN) for the prevention of a second stroke. However, for the treatment of a patient pragmatism is necessary and the costs for the system have to be regarded. Furthermore, clinical studies can leave unanswered questions. For the choice of the aggregation inhibitor the individual situation of the patient should be regarded. Blood pressure has to be observed and regulated. Lipid-lowering agents are effective for elderly patients as prevention, but not as first choice treatment. For every medical treatment, practical and clinical usefulness should be regarded.
引用
收藏
页码:789 / +
页数:6
相关论文
共 50 条
  • [21] Secondary stroke prevention: recent developments
    Kranidiotis, Georgios
    SCIENTIFIC CHRONICLES, 2019, 24 (03) : 266 - 276
  • [22] Antiplatelet Drugs for Ischemic Stroke Prevention
    Leys, Didier
    Balucani, Clotilde
    Cordonnier, Charlotte
    CEREBROVASCULAR DISEASES, 2009, 27 : 120 - 125
  • [23] Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines
    Hankey, Graeme J.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (06) : 1453 - 1462
  • [24] Ischemic stroke prevention: An update on antiplatelet therapy
    Neill, KK
    Luer, MS
    NEUROLOGICAL RESEARCH, 2002, 24 (04) : 381 - 388
  • [25] Antiplatelet Strategies for Secondary Prevention of Stroke and TIA
    Ishida, Koto
    Messe, Steven R.
    CURRENT ATHEROSCLEROSIS REPORTS, 2014, 16 (11)
  • [26] New Findings in Primary and Secondary Stroke Prevention
    Weimar, C.
    Weber, R.
    Hajjar, K.
    Diener, H. C.
    AKTUELLE NEUROLOGIE, 2013, 40 (02) : 70 - 78
  • [27] Antiplatelet Therapy for Secondary Prevention of Ischemic Stroke
    Pace, Wilson D.
    Earl, Ali
    Bryant, Casey
    Hansen, Cory
    US PHARMACIST, 2020, 45 (01) : HS8 - HS12
  • [28] Validity of Composite Outcomes in Meta-Analyses of Stroke Prevention Trials: The Case of Aspirin
    McGrath, Emer
    O'Conghaile, Aengus
    Eikelboom, John W.
    Dinneen, Sean F.
    Oczkowski, Colin
    O'Donnell, Martin J.
    CEREBROVASCULAR DISEASES, 2011, 32 (01) : 22 - 27
  • [29] Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness
    Rothlisberger, Julia M.
    Ovbiagele, Bruce
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2015, 4 (04) : 377 - 384
  • [30] Prevention of cardioembolic stroke
    Gil Nunez, Antonio
    NEUROLOGIA, 2012, 27 : 15 - 26